1. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers 
J.F. McLeod, J.M. Leempoels, S.X. Peng, S.L. Dax, L.J. Myers, F.J. Golder 
British Journal of Anaesthesia 
Volume 113, Issue 5, Pages (November 2014)
DOI: /bja/aeu182
Copyright © 2014 The Author(s) Terms and Conditions

2. Fig 1
Chemical structure of GAL-021 (2-N,O-dimethylhydroxylamino-4,6-bispropylamino-S-triazine). The drug product is prepared as a H2SO4 salt.
British Journal of Anaesthesia  , DOI: ( /bja/aeu182)
Copyright © 2014 The Author(s) Terms and Conditions

3. Fig 2
Percentage change in minute ventilation (a) and E C O 2 ′ (b) after initiation of GAL-021 infusion (mg kg−1 h−1). Only the three highest dose infusion rates are displayed for clarity. Periods 6 and 7 with identical infusion 0.72 mg kg−1 h−1 rates were pooled for time course analysis as described in the Methods section [mean (sem), *P<0.05].
British Journal of Anaesthesia  , DOI: ( /bja/aeu182)
Copyright © 2014 The Author(s) Terms and Conditions

4. Fig 3
Mean plasma concentration–time profiles of GAL-021 after i.v. infusion to healthy volunteer. Inset panel contains the same data plotted in log–linear graph. The mean concentration is displayed. For clarity, error bar is not included. The mean and sds for key PK parameters may be found in Table 4.
British Journal of Anaesthesia  , DOI: ( /bja/aeu182)
Copyright © 2014 The Author(s) Terms and Conditions

5. Fig 4
Plasma concentration at 1-h infusion timepoint as a function of infusion rate for GAL-021 (a). Total systemic exposure (AUC0–∞) as a function of infusion dose for GAL-021 (b). The solid line denotes the regression line derived from the power model. The results of the power analysis are included in each graph.
British Journal of Anaesthesia  , DOI: ( /bja/aeu182)
Copyright © 2014 The Author(s) Terms and Conditions